No abstract

Moxifloxacin and imunofan peptide concentrations - dependent Clostridium difficile growth rate was analyzed in vitro. In the course of our study, it was revealed imunofan peptide at concentrations 0.05, 0.25 μg/ml has antimicrobial characteristics against toxigenic C. difficile strain. At the same time, with the peptide and the antibiotic combined interaction, we observed moxifloxacin concentration 0-1.5 MIC stimulates C. difficile growth, regardless of the imunofan concentration. Concentrations of maximum growth inhibition for C. difficile were also established with the combined effects peptide imunofan and antibiotic moxifloxacin - 1.5 μg/ml and 2.5 MIC, respectively.

No abstract

Patients in pediatric oncological hospitals are at risk of developing a Clostridium difficile infection. The purpose of this study was to determine the risk of developing a Clostridium difficile infection in patients who are treated with antibiotics of different classes and combinations by way of a retrospective analysis of 122 patient records. It was shown that the administration of antibacterial chemotherapeutic drugs that belong to the classes of nitrofurans (enterofuryl), sulfonamides (biseptol), cephalosporins, and macrolides/azalides significantly increased the risk of developing a Clostridium difficile infection in pediatric patients. On the contrary, treatment with antibiotics of different classes, such as linezolid, colistin, and metronidazole, significantly reduced the risk of developing a Clostridium difficile infection. The use of penicillins, aminoglycosides, fluoroquinolones, glycopeptides, and carbapenems was not associated with the risk of developing a Clostridium difficile infection in pediatric patients. The administration of one or two antimicrobial drugs of different classes increased the risk of developing a Clostridium difficile infection while a combination of three different types of antimicrobial drugs lowered the rate of this infection in pediatric patients.